Publicacións (36) Publicacións de JUAN CARLOS ALADOS ARBOLEDAS

2023

  1. Anticipatory Antifungal Treatment in Critically Ill Patients with SARS-CoV-2 Pneumonia

    Journal of Fungi, Vol. 9, Núm. 3

  2. Co-02. Estado actual de la hepatitis delta en andalucía. Implantacion del diagnostico en un solo paso.

    Revista andaluza de patología digestiva, Vol. 46, Núm. 5, pp. 298-299

2022

  1. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

  2. Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe

    Journal of Hepatology, Vol. 77, Núm. 2, pp. 326-331

2021

  1. Diagnostic pre-screening method based on N-gene dropout or delay to increase feasibility of SARS-CoV-2 VOC B.1.1.7 detection

    Diagnostic Microbiology and Infectious Disease, Vol. 101, Núm. 4

  2. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810

  3. Limited Value of Single Sampling for IgM Antibody Determination as a Diagnostic Approach for Acute Hepatitis E Virus Infection

    Microbiology Spectrum, Vol. 9, Núm. 1, pp. 1-5

  4. The prognostic value of toxin B and binary toxin in Clostridioides difficile infection

    Gut Microbes, Vol. 13, Núm. 1

  5. Vaccinated patients admitted in icu with severe pneumonia due to sars-cov-2: A multicenter pilot study

    Journal of Personalized Medicine, Vol. 11, Núm. 11

  6. Validación clínica de un test serológico rápido semicuantitativo para pacientes infectados de covid-19 y determinación de la seroprevalencia en una población sanitaria

    Revista española de patología torácica, Vol. 33, Núm. 4, pp. 217-223

2020

  1. Current position of viral load versus hepatitis C core antigen testing

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, pp. 12-18

  2. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 71, Núm. 9, pp. 2354-2362

  3. Sample pooling for SARS-CoV-2 RT-PCR screening

    Clinical Microbiology and Infection, Vol. 26, Núm. 12, pp. 1687.e1-1687.e5

  4. The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain

    Scientific Reports, Vol. 10, Núm. 1

  5. Towards the elimination of hepatitis C: Implementation of reflex testing in Andalusia

    Revista Espanola de Enfermedades Digestivas, Vol. 112, Núm. 7, pp. 515-519

2019

  1. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals

    AIDS, Vol. 33, Núm. 7, pp. 1167-1174

  2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

    Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888

  3. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641

2018

  1. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis

    PLoS ONE, Vol. 13, Núm. 7

2017

  1. A cost-saving strategy for processing isolated uropathogens in community-acquired urinary tract infections

    Journal of Microbiological Methods, Vol. 139, pp. 130-134